UA70299C2 - Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin - Google Patents

Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin Download PDF

Info

Publication number: UA70299C2
Authority: UA; Ukraine
Prior art keywords: compound; pharmaceutically acceptable; differs; insulin; acceptable form
Prior art date: 1997-06-18

Application number

UA99126881A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Smithkline Beecham P L S Smith

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-18

Filing date

1998-06-15

Publication date

2004-10-15

1998-06-15 Application filed by Smithkline Beecham P L S Smith filed Critical Smithkline Beecham P L S Smith

2004-10-15 Publication of UA70299C2 publication Critical patent/UA70299C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 40
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 38
206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 23
102000004877 Insulin Human genes 0.000 title claims abstract description 19
108090001061 Insulin Proteins 0.000 title claims abstract description 19
229940125396 insulin Drugs 0.000 title claims abstract description 19
150000001875 compounds Chemical class 0.000 claims abstract description 58
241000124008 Mammalia Species 0.000 claims abstract description 6
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
238000012876 topography Methods 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 abstract description 2
230000003000 nontoxic effect Effects 0.000 abstract description 2
239000000203 mixture Substances 0.000 description 26
208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
239000003826 tablet Substances 0.000 description 9
206010022489 Insulin Resistance Diseases 0.000 description 5
230000033228 biological regulation Effects 0.000 description 5
-1 for example Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
235000008504 concentrate Nutrition 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002641 glycemic effect Effects 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
150000002688 maleic acid derivatives Chemical class 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
150000001467 thiazolidinediones Chemical class 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010061692 Benign muscle neoplasm Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
201000004458 Myoma Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Obesity (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)

UA99126881A 1997-06-18 1998-06-15 Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin UA70299C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9712866.4A GB9712866D0 (en)	1997-06-18	1997-06-18	Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en)	1997-06-18	1998-06-15	Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number	Publication Date
UA70299C2 true UA70299C2 (en)	2004-10-15

Family

ID=10814527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99126881A UA70299C2 (en)	1997-06-18	1998-06-15	Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin

Country Status (30)

Country	Link
EP (1)	EP0999837A1 (hu)
JP (1)	JP2002504138A (hu)
KR (1)	KR20010013843A (hu)
CN (1)	CN1133431C (hu)
AP (1)	AP1287A (hu)
AR (2)	AR012997A1 (hu)
AU (1)	AU8216398A (hu)
BG (1)	BG104059A (hu)
BR (1)	BR9810444A (hu)
CA (1)	CA2294141A1 (hu)
CO (1)	CO4940454A1 (hu)
DZ (1)	DZ2521A1 (hu)
EA (1)	EA004800B1 (hu)
GB (1)	GB9712866D0 (hu)
HU (1)	HUP0003260A3 (hu)
ID (1)	ID23951A (hu)
IL (1)	IL133143A0 (hu)
IN (1)	IN189723B (hu)
MA (1)	MA26511A1 (hu)
NO (1)	NO996265D0 (hu)
OA (1)	OA11517A (hu)
PE (1)	PE104499A1 (hu)
PL (1)	PL343123A1 (hu)
SK (1)	SK179399A3 (hu)
TR (1)	TR199903095T2 (hu)
TW (1)	TW587937B (hu)
UA (1)	UA70299C2 (hu)
UY (1)	UY25050A1 (hu)
WO (1)	WO1998057636A1 (hu)
ZA (1)	ZA985237B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291495B1 (en) *	1997-02-24	2001-09-18	Robert B. Rieveley	Method and composition for the treatment of diabetes
TWI249401B (en)	1999-04-14	2006-02-21	Takeda Chemical Industries Ltd	Agent for improving ketosis
MXPA01010820A (es)	1999-04-23	2002-06-04	Smithkline Beecham Plc	Composicion farmaceutica novedosa.
DE60036367T2 (de) *	1999-06-21	2008-05-29	Eli Lilly And Co., Indianapolis	Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
JP2003503356A (ja) *	1999-06-25	2003-01-28	メドトロニックミニメドインコーポレイテッド	多剤糖尿病治療
US6468507B1 (en) *	2000-05-01	2002-10-22	Aeropharm Technology, Inc.	Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) *	2000-09-29	2000-11-15	Smithkline Beecham Plc	Novel pharmaceutical
US6852694B2 (en)	2001-02-21	2005-02-08	Medtronic Minimed, Inc.	Stabilized insulin formulations
US6531461B1 (en)	2001-06-04	2003-03-11	Louis Obyo Obyo Nelson	Medicament for the treatment of diabetes
US20020198203A1 (en) *	2001-06-07	2002-12-26	Wyeth	Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en)	2001-06-28	2004-05-18	Metronic Minimed, Inc.	Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
ES2295692T3 (es) *	2002-11-08	2008-04-16	F. Hoffmann-La Roche Ag	Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
US7264813B2 (en)	2003-09-24	2007-09-04	Nikken Sohonsha Corporation	Therapeutic uses of Dunaliella powder
CN102389427A (zh) *	2011-10-10	2012-03-28	成都恒瑞制药有限公司	含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1714652A3 (en) *	1993-09-15	2007-01-17	Sankyo Company, Limited	Use of thiazolidinediones to prevent or delay onset of niddm
KR19990036290A (ko) *	1995-08-10	1999-05-25	로즈 암스트롱	비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
ATE259227T1 (de) *	1995-09-18	2004-02-15	Ligand Pharm Inc	Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten

1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
1998
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Application Discontinuation
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
1999
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
- 1999-12-17 NO NO996265A patent/NO996265D0/no not_active Application Discontinuation
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown

Also Published As

Publication number	Publication date
GB9712866D0 (en)	1997-08-20
PL343123A1 (en)	2001-07-30
AR015894A1 (es)	2001-05-30
ID23951A (id)	2000-06-08
CO4940454A1 (es)	2000-07-24
EA004800B1 (ru)	2004-08-26
AP1287A (en)	2004-06-26
IN189723B (hu)	2003-04-19
TW587937B (en)	2004-05-21
SK179399A3 (en)	2000-11-07
EA200000042A1 (ru)	2000-08-28
AR012997A1 (es)	2000-11-22
DZ2521A1 (fr)	2003-02-08
CN1260715A (zh)	2000-07-19
HUP0003260A3 (en)	2001-12-28
KR20010013843A (ko)	2001-02-26
NO996265L (no)	1999-12-17
CA2294141A1 (en)	1998-12-23
HUP0003260A2 (hu)	2001-05-28
EP0999837A1 (en)	2000-05-17
JP2002504138A (ja)	2002-02-05
IL133143A0 (en)	2001-03-19
AP9901718A0 (en)	1999-12-31
OA11517A (en)	2004-02-04
TR199903095T2 (xx)	2000-08-21
BR9810444A (pt)	2000-09-05
BG104059A (en)	2000-10-31
AU8216398A (en)	1999-01-04
MA26511A1 (fr)	2004-12-20
PE104499A1 (es)	2000-01-13
UY25050A1 (es)	2000-09-29
NO996265D0 (no)	1999-12-17
ZA985237B (en)	2000-02-17
WO1998057636A1 (en)	1998-12-23
CN1133431C (zh)	2004-01-07

Publication	Publication Date	Title
ES2284212T3 (es)	2007-11-01	Tratamiento de diabetes con tiazolidinadiona y metformina.
UA70299C2 (en)	2004-10-15	Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin
UA70303C2 (uk)	2004-10-15	Комбінація, що містить тіазолідиндіон, засіб стимуляції секреції інсуліну та дигуанід, спосіб лікування цукрового діабету
ES2283064T3 (es)	2007-10-16	Tratamiento de diabetes con tiazolin-diona y sulfonilurea.
NZ501345A (en)	2001-10-26	Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent
JP2005247865A (ja)	2005-09-15	チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
UA68352C2 (en)	2004-08-16	Method for treatment of diabetes mellitus with thiazolidin and metformin
MXPA99012065A (en)	2000-08-01	Treatment of diabetes with rosiglitazone and insulin
NZ515554A (en)	2003-09-26	Treatment of diabetes with thiazolidinedione and metformin
NZ518076A (en)	2004-02-27	5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
MXPA99012098A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
HU226960B1 (en)	2010-03-29	Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes
MXPA99012078A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and metformin